Sonalasense, Inc.

Sonalasense, Inc., doing business as Sonalasense Inc., is a corporate entity registered to receive federal contract and grant awards. The company appears to specialize in developing non-invasive treatments for brain cancers, particularly glioblastoma multiforme and diffuse intrinsic pontine glioma (DIPG), using a combination of pharmaceutical drugs and MRI-guided focused ultrasound technology.

Through its prime federal grant awards, Sonalasense has received funding from agencies such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to conduct research and clinical trials for its sonodynamic therapy (SDT) treatment approach. This involves administering the drug 5-aminolevulinic acid (ALA) intravenously, followed by targeted application of MRI-guided focused ultrasound to activate a metabolite of the drug, causing oxidative stress and apoptosis in cancer cells. The company has completed pre-clinical studies demonstrating the safety and efficacy of this approach in animal models and is now conducting phase 2 clinical trials to evaluate its potential for treating recurrent glioblastoma multiforme and DIPG in human patients. The grant awards have provided funding for activities such as developing assays for monitoring drug levels, determining appropriate drug and energy doses, assessing safety and efficacy in patients, and ultimately seeking FDA marketing approval for the SDT combination therapy.